Huge Growth in Asian In Vitro Diagnostic Markets

By HospiMedica staff writers
Posted on 16 Oct 2002
Revenues in the top five Asian clinical diagnostic markets are currently near US$3.5 billion, and double-digit growth is not uncommon in many segments now considered moribund in Western Europe and the United States, according to a new study from Kalorama Information, an imprint of MarketResearch (NY, NY, USA).

The study found widely varying results among the top markets, as political and economic changes reshape many of the countries in the region. Japan, by far the largest market in Asia, represents a stable, mature market, while China is in the midst of major changes.

"The five top markets in Asia have little in common except that they share a continent,” said Carl McEvoy, one of the study's authors. "Japan, like North America and Western Europe, is an entirely mature market. But at the other extreme lie China and India. China's growth rate has actually increased in the past two years, and its gains are truly surprising.”

Contributing factors are China's entry into the World Trade Organization, the unmet need of a growing population in China and India, and Korea's continuing recovery from the Asian economic crisis of the 1990s.

The study analyzes six segments in each of the top five markets, providing revenues, growth rates, and market share for both instruments and reagents. The study also discusses top competitors and provides an overview of the IVD business in each of these markets.




Related Links:
MarketResearch

Latest Business News